(Total Views: 93)
Posted On: 02/27/2024 3:13:37 PM
Post# of 35599
Medical Breakthrough Stocks Under $1: $OCGN, $VERO, $RSCI, $VTAK, $ENVB
https://thestreetreports.com/medical-advancem...vtak-envb/
Ocugen Inc. (NASDAQ: OCGN) emerges as a noteworthy biotech stock for investors to monitor in upcoming trading sessions. On February 22, 2024, Ocugen Inc. reported the successful completion of the initial cohort in the Phase 1/2 GARDian clinical trial for its OCU410ST product. This product, a modifier gene therapy candidate, aims to address Stargardt disease, an orphan blindness condition affecting approximately 35,000 individuals solely in the United States. Dr. Arun Upadhyay, Ocugen’s Head of Research and Development and Chief Scientific Officer highlighted this achievement as a significant clinical milestone for the company. OCU410ST represents a pioneering, potentially one-time therapy for Stargardt disease sufferers. With a surge in after-hours trading on February 26, 2024, keeping a close watch on Ocugen’s stock performance could prove prudent.
Venus Concept Inc. (NASDAQ: VERO), a leading global provider of medical aesthetic technology, revealed on February 23, 2024, that it had engaged in a registered direct offering, adhering to NASDAQ regulations regarding market pricing. Under this agreement, the company plans to offer 817,748 shares of its common stock at a price of $1.645 per share. Simultaneously, Venus Concept Inc. will conduct a private placement, issuing unregistered warrants enabling the purchase of up to 817,748 shares of common stock at an exercise price of $1.34 per share. These warrants will be immediately exercisable upon issuance and will remain valid for a period of five years from the date of issuance.
Redwood Scientific Technologies Inc. (OTC: RSCI) The company witnessed a remarkable uptick in its stock performance across a span of 5 trading sessions, achieving an impressive gain of 97.95%. Concurrently, the trading volume for the stock exhibited significant vigor. On February 6, 2024, it was revealed that Redwood Scientific Technologies Inc. had entered a partnership with Jeeva Clinical Trials. This collaboration is geared towards initiating clinical effectiveness studies for Redwood Scientific Technologies’ TBX-free oral strips, designed to aid in smoking and e-cigarette cessation efforts.
Catheter Precision (NYSE American: VTAK), a leading technology firm specializing in state-of-the-art electrophysiology techniques for treating cardiac arrhythmias, introduced its LockeT suture closure device at the upcoming International Symposium on Left Atrial Appendage, scheduled for March 1-2, 2024, at the Intercontinental New York Times Square. This event is poised to draw worldwide attention and provide essential education for healthcare professionals in cardiology, electrophysiology, and internal medicine. Additionally, Catheter Precision Inc. showcased its latest innovations at the AF Symposium conference held from February 1-3, 2024, in Boston, Massachusetts. Catheter Precision Inc. (NYSE American: VTAK) gained recognition as a prominent innovator in the swiftly growing medical manufacturing sector, notably highlighted in a feature in “MedTech Outlook.” With a focus on electrophysiology (EP) technology, delve into the complete interview in “MedTech Outlook” for thorough insights, and also explore the EP Lab Digest Case Study.
Enveric Biosciences (NASDAQ: ENVB) operates as a biotechnology company dedicated to advancing neuroplastogenic small-molecule therapeutics aimed at addressing conditions such as anxiety, depression, and addiction-related disorders. On February 23, 2024, Enveric Biosciences disclosed an arrangement to divest a specific cancer-focused patent portfolio, the financial terms of which were not disclosed. Despite this transaction, the company affirmed its commitment to advancing EB 003, its primary candidate, through ongoing investment and research efforts.
https://thestreetreports.com/medical-advancem...vtak-envb/
Ocugen Inc. (NASDAQ: OCGN) emerges as a noteworthy biotech stock for investors to monitor in upcoming trading sessions. On February 22, 2024, Ocugen Inc. reported the successful completion of the initial cohort in the Phase 1/2 GARDian clinical trial for its OCU410ST product. This product, a modifier gene therapy candidate, aims to address Stargardt disease, an orphan blindness condition affecting approximately 35,000 individuals solely in the United States. Dr. Arun Upadhyay, Ocugen’s Head of Research and Development and Chief Scientific Officer highlighted this achievement as a significant clinical milestone for the company. OCU410ST represents a pioneering, potentially one-time therapy for Stargardt disease sufferers. With a surge in after-hours trading on February 26, 2024, keeping a close watch on Ocugen’s stock performance could prove prudent.
Venus Concept Inc. (NASDAQ: VERO), a leading global provider of medical aesthetic technology, revealed on February 23, 2024, that it had engaged in a registered direct offering, adhering to NASDAQ regulations regarding market pricing. Under this agreement, the company plans to offer 817,748 shares of its common stock at a price of $1.645 per share. Simultaneously, Venus Concept Inc. will conduct a private placement, issuing unregistered warrants enabling the purchase of up to 817,748 shares of common stock at an exercise price of $1.34 per share. These warrants will be immediately exercisable upon issuance and will remain valid for a period of five years from the date of issuance.
Redwood Scientific Technologies Inc. (OTC: RSCI) The company witnessed a remarkable uptick in its stock performance across a span of 5 trading sessions, achieving an impressive gain of 97.95%. Concurrently, the trading volume for the stock exhibited significant vigor. On February 6, 2024, it was revealed that Redwood Scientific Technologies Inc. had entered a partnership with Jeeva Clinical Trials. This collaboration is geared towards initiating clinical effectiveness studies for Redwood Scientific Technologies’ TBX-free oral strips, designed to aid in smoking and e-cigarette cessation efforts.
Catheter Precision (NYSE American: VTAK), a leading technology firm specializing in state-of-the-art electrophysiology techniques for treating cardiac arrhythmias, introduced its LockeT suture closure device at the upcoming International Symposium on Left Atrial Appendage, scheduled for March 1-2, 2024, at the Intercontinental New York Times Square. This event is poised to draw worldwide attention and provide essential education for healthcare professionals in cardiology, electrophysiology, and internal medicine. Additionally, Catheter Precision Inc. showcased its latest innovations at the AF Symposium conference held from February 1-3, 2024, in Boston, Massachusetts. Catheter Precision Inc. (NYSE American: VTAK) gained recognition as a prominent innovator in the swiftly growing medical manufacturing sector, notably highlighted in a feature in “MedTech Outlook.” With a focus on electrophysiology (EP) technology, delve into the complete interview in “MedTech Outlook” for thorough insights, and also explore the EP Lab Digest Case Study.
Enveric Biosciences (NASDAQ: ENVB) operates as a biotechnology company dedicated to advancing neuroplastogenic small-molecule therapeutics aimed at addressing conditions such as anxiety, depression, and addiction-related disorders. On February 23, 2024, Enveric Biosciences disclosed an arrangement to divest a specific cancer-focused patent portfolio, the financial terms of which were not disclosed. Despite this transaction, the company affirmed its commitment to advancing EB 003, its primary candidate, through ongoing investment and research efforts.
(0)
(0)Scroll down for more posts ▼
